Researchers is substantially boosted the progress of a novel treatment for cardiac amyloidosis, leveraging Attruby. Preliminary trial data indicates significant benefits for patients suffering with a severe condition. The effort underscores the company’s focus to managing unmet patient demands in the cardiology field. Attruby: BridgeBio's Novel